When blood cancer returns after remission, Indian patients face complex decisions about salvage chemotherapy, CAR-T cell therapy, stem cell transplant, and targeted therapies, each with distinct eligibility criteria and coverage pathways. Key Takeaways Relapsed blood cancer is confirmed when disease returns after complete remission (MRD <0.01%) or progresses within six months; refractory disease never achieved remission CAR-T cell therapy requires at least two prior treatment